The short version of ipamorelin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-25. Anything still debated is marked as such rather than presented as settled.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
==== Tumor necrosis factor (TNF) ==== TNF breaks down muscle and fat while stopping new muscle and fat cells from forming by activating the ubiquitin proteasome pathway. It also triggers the release of other cytokines that also speed up muscle loss. Since this process is very complex, cachexia is unlikely to be caused by one molecule. While it is thought to be produced by immune cells called macrophages, scientists are still unsure of exactly where TNF is produced in cachexia.
NRT, other prescribed pharmaceuticals, and professional counselling or support also help many smokers. However, up to three-quarters of ex-smokers report having quit without assistance ("cold turkey" or cut down then quit), and cessation without professional support or medication may be the most common method used by ex-smokers. The number of nicotinic receptors in the brain returns to the level of a nonsmoker between 6 and 12 weeks after quitting. In 2019, the FDA authorized the selling of low-nicotine cigarettes in hopes of lowering the number of people addicted to nicotine.
NAA60 is a protein belonging to the family of N-terminal acetyltransferases (NATs), which catalyze the transfer of an acetyl group from acetyl-coenzyme A (Ac-CoA) to the N-terminus of proteins. NAA60 is specifically localized to the Golgi apparatus and can acetylate membrane proteins post-translationally that have cytosolic N-termini starting with methionine followed by hydrophobic- or amphipathic-type amino acids (ML-, MI-, MF-, MY-, and MK-).
Sources: en.wikipedia.org
=== Mouse model === A mouse model of progeria exists, though in the mouse, the LMNA prelamin A is not mutated. Instead, ZMPSTE24, the specific protease that is required to remove the C-terminus of prelamin A, is missing. Both cases result in the buildup of farnesylated prelamin A on the nuclear membrane and in the characteristic nuclear LMNA blebbing. In 2020, BASE editing was used in a mouse model to target the LMNA gene mutation that causes the progerin protein instead of the healthy Lamin A while in 2023 a study designed a peptide that prevented progerin from binding to BubR1 which is known to regulate aging in mice.
Liesegang: in 1927, he placed filter strips in closed containers with atmospheres saturated by solvents, and in 1943 he began using discrete spots of sample adsorbed to filter paper, dipped in pure solvent to achieve separation. This method, essentially identical to modern paper chromatography, was published just before the independent—and far more influential—work of Archer Martin and his collaborators that inaugurated the widespread use of paper chromatography. In 1897, the American chemist David Talbot Day (1859–1915), then serving with the U.S. Geological Survey, observed that crude petroleum generated bands of color as it seeped upwards through fine-grained clay or limestone. In 1900, he reported his findings at the First International Petroleum Congress in Paris, where they created a sensation.
... consciously and unconsciously reflected a number of deep American anxieties that grew out of more than two decades of the Cold War. By the mid–1960s, some Americans began to critique what they saw as mindless nationalism. This unthinking patriotism had coalesced as part of a liberal consensus grounded in confidence in the essential soundness of American society as well as the assumption of a pervasive communist threat to the U.S. and its allies. Many supporters of the liberal consensus believed that economic growth and development would solve any remaining social inequalities while damping class conflict. Like Bernardi, Austin discusses racial stereotypes in the episode. Citing Bernardi, he argues that, instead of considering "the Yangs as noble savages, the Yangs can now be seen as an example of the result of mindless nationalism run amok, albeit still salvageable in Roddenberry's ever-optimistic view of the future." He adds, "Many of the qualities ascribed to the Yangs mirrored terms used to describe the 'yellow peril' at an earlier time in U.S. history. For example, Tracy, after noting directly that the Yangs are white, describes them as vicious and deceptive enemies who cannot communicate intelligently." In "The Omega Glory", a 2006 essay reflecting on stories that have tried to imagine the future, Michael Chabon says, "Eed plebnista, intoned the devolved Yankees, in the Star Trek episode 'The Omega Glory', who had somehow managed to hold on to and venerate as sacred gobbledygook the Preamble to the Constitution, norkon forden perfectunun.
Sources: en.wikipedia.org
===== History of Vitatron ===== 1956: Vitatron founded 1962: First Implantable pacemakers 1981: Microprocessor-driven, software-based pacemaker (DPG1) 1982: Rate Responsive pacemaker (TX1) 1984: Quintech DDD with automatic upper rate behavior ("mode switch") 1988: Daily Learn algorithm (Rhythmyx) 1997: First upgradeable pacemaker system with dedicated AF diagnostics, rate and rhythm control therapy. 2003: Vitatron goes digital: 1st Vitatron C-Series, the world's first fully digital pacemaker. 2004: 2nd Vitatron C-Series, digital, fast pacemaker. 2004: Vitatron T-Series: The full picture, digital pacemaker system. 2005: Vitatron C-Series, A3 models, a new top line range of digital pacemakers for bradycardic patients.
== Further reading == Mortison, JD; Sherman, DH (2010). "Frontiers and opportunities in chemoenzymatic synthesis". J Org Chem. 75 (21): 7041–51. doi:10.1021/jo101124n. PMC 2966535. PMID 20882949. Kim, Jinhyun; Lee, Sahng Ha; Tieves, Florian; Paul, Caroline E.; Hollmann, Frank; Park, Chan Beum (5 July 2019). "Nicotinamide adenine dinucleotide as a photocatalyst". Science Advances. 5 (7): eaax0501. doi:10.1126/sciadv.aax0501.
Colin Ayton Greenhalgh, Principal, Hills Road Sixth Form College, Cambridge. For services to Education. Ian Gregg, Chairman, River Tweed Commissioners and Tweed Foundation. For services to Salmon and Trout Fishing. Vernon Charles Grove, Administrator, Wales and Chester Circuit, Lord Chancellor's Department. Rex Farrow Gyngell, . For political and public service. Arthur Barry Haines, Chair, Aerodynamics Group, Royal Aeronautical Society. For services to Aerodynamics. Eunice Hanna. For political service. Lieutenant Colonel Grattan Herbert Hart, . For services to the Royal British Legion in Sussex. Robert James Hasson, Assistant Controller (Collection and Personnel), Board of Inland Revenue. Anthony Roger Heath. For services to the Administration of Justice. Jennifer Mary Toresen, Lady Hemingford. For services to the community in Hemingford Abbots, Cambridgeshire and to the British Red Cross Society. Desmond Charles Henley, Embalmer. For services in the Aftermath of Disasters. Damon Graham Hill. For services to Motor Racing. John William Hoaen, Grade 7, Department of Trade and Industry. Margaret Edith Hobrough, Principal and Chief Executive, Godalming Sixth Form College, Surrey. For services to Education. Brigadier David Hendry Hodge, . For services to the Territorial Auxiliary and Volunteer Reserve Association in the North of England. The Reverend Roger Graham Holloway. For services to Export. John Hood. For services to Industry. John Trevor Hopkins, Headmaster, Bishop Stopford School, Kettering, Northamptonshire. For services to Education.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.